GSK-AC4117410

Study Sponsor: GSK

Study Title

A 24 Week Randomised, Double blind and Placebo controlled Study to Evaluate the Efficacy and Safety of 62.5 mcg Umeclidinium Inhalation Powder Delivered Once daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease

Medicine or Vaccine (generic name)

umeclidinium bromide

Sponsor Identification Number

AC4117410

Trial Registry Identification Number(#'s)

NCT02184611

Medical Condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=117410

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT02184611

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

May 2020